NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today reported 5 percent revenue growth for the third quarter, with particularly strong growth coming from its Specialty Diagnostics segment, and raised its full-year top- and bottom-line guidance.

The Waltham, Mass.-based provider of labware, research products, and diagnostics reported total revenues of $3.09 billion for the three months ended Sept. 29, up from Q3 2011 revenues of $2.93 billion. It beat analysts' consensus estimate for revenues of $2.99 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.